According to GuruFocus Insider Data, these are the largest CEO buys during the past week.
Brigham Minerals CEO bought 36,111 shares
Brigham Minerals Inc. (MNRL, Financial) CEO Robert M. Roosa bought 36,111 shares on April 23 at a price of $18.00. The price of the stock has increased by 13.83% since.
Brigham Minerals acquires and manages a portfolio of mineral and royalty interests in some of the most active resource basins across the continental U.S., including the Permian Basin in Texas and New Mexico, the SCOOP and STACK plays in the Anadarko Basin of Oklahoma, the Denver-Julesburg (DJ) Basin in Colorado and Wyoming, and the Williston Basin in North Dakota. The company has a market cap of $975 million. Its shares traded at $20.49 with a price-earnings ratio of 0.22 as of April 26.
On April 9, the company announced that it had launched an initial public offering of 13.5 million shares of its Class A common stock at an anticipated initial offering price between $15.00 and $18.00 per share. The shares have been authorized for listing on the New York Stock Exchange under the ticker symbol “MNRL,” subject to official notice of issuance.
Chief Financial Officer Blake C. Williams bought 19,444 shares on April 23 at a price of $18. The price of the stock has increased by 13.83% since.
Executive Chairman Ben M. Brigham bought 111,110 shares on April 23 at a price of $18. The price of the stock has increased by 13.83% since.
Director Harold D. Carter bought 40,000 shares on April 23 at a price of $18. The price of the stock has increased by 13.83% since.
Director John R. Sult bought 15,000 shares on April 23 at a price of $18. The price of the stock has increased by 13.83% since.
Turning Point Therapeutics CEO bought 12,000 shares
Turning Point Therapeutics Inc. (TPTX, Financial) President and CEO Athena Countouriotis bought 12,000 shares on April 22 at a price of $18.00. The price of the stock has increased by 73.78% since.
Turning Point Therapeutics is a clinical-stage biopharmaceutical company that designs and develops novel small molecule, targeted oncology therapies to address key limitations of existing therapies and improve the lives of patients. The company has a market cap of $927 million. Its shares traded at $31.28 as of April 26.
On April 22, the company announced the closing of its initial public offering of 10,637,500 shares of its common stock at a price to the public of $18.00 per share.
Vice President of Finance and Administration Brian Lee Baker bought 2,800 shares on April 22 at a price of $18. The price of the stock has increased by 73.78% since.
Director Orbimed Advisors LLC bought 360,000 shares on April 22 at a price of $18. The price of the stock has increased by 73.78% since.
Director Hongbo Lu bought 60,000 shares on April 22 at a price of $18. The price of the stock has increased by 73.78% since.
Director Carl L. Gordon bought 360,000 shares on April 22 at a price of $18. The price of the stock has increased by 73.78% since.
Director Simeon George bought 325,000 shares on April 22 at a price of $18. The price of the stock has increased by 73.78% since.
OPKO Health CEO bought 80,000 shares
OPKO Health Inc. (OPK, Financial) CEO, Chairman and 10% Owner Phillip Frost bought 80,000 shares on April 22 at a price of $2.32. The price of the stock has increased by 6.03% since.
The diversified health care company seeks to establish industry-leading positions in large, rapidly growing markets. The company has a market cap of $1.52 billion. Its shares traded at $2.46 as of April 26.
Net loss for the fourth quarter of 2018 was $76.1 million compared to $217.9 million for the comparable quarter of 2017.
Frost previously bought 20,000 shares on April 12 at a price of $2.5; 10,000 shares on April 15 at a price of $2.47; 10,000 shares on April 16 at a price of $2.5; and 50,000 shares on April 17 at a price of $2.42.
ARMOUR Residential Co-CEOs bought 5,000 shares
ARMOUR Residential REIT Inc. (ARR, Financial) Co-CEO and Chief Investment Officer Scott Ulm bought 5,000 shares on April 26 at a price of $19.32. Co-CEO and President Jeffrey J. Zimmer also bought 5,000 shares on April 26 at a price of 19.32. The price of the stock has increased by 1.6% since.
ARMOUR Residential REIT is a real estate investment trust that primarily invests in residential mortgage-backed securities, or RMBS. The company's investment portfolio is composed of mortgage-backed securities, adjustable-rate mortgage securities, and multifamily mortgage-backed securities. The company has a market cap of $1.17 billion. Its shares traded at $19.63 as of April 26.
Net loss for the first quarter of 2019 was $114.38 million compared to net income of $44.75 million for the prior-year period.
For the complete list of stocks that were bought by their company CEOs, go to: CEO Buys.
Disclosure: I do not own stock in any of the companies mentioned.
Not a Premium Member of GuruFocus? Sign up for a free 7-day trial here.
